JP2015512433A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512433A5
JP2015512433A5 JP2015503848A JP2015503848A JP2015512433A5 JP 2015512433 A5 JP2015512433 A5 JP 2015512433A5 JP 2015503848 A JP2015503848 A JP 2015503848A JP 2015503848 A JP2015503848 A JP 2015503848A JP 2015512433 A5 JP2015512433 A5 JP 2015512433A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
weight
disintegrant
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015503848A
Other languages
English (en)
Japanese (ja)
Other versions
JP6320990B2 (ja
JP2015512433A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/056867 external-priority patent/WO2013149987A1/en
Publication of JP2015512433A publication Critical patent/JP2015512433A/ja
Publication of JP2015512433A5 publication Critical patent/JP2015512433A5/ja
Application granted granted Critical
Publication of JP6320990B2 publication Critical patent/JP6320990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015503848A 2012-04-04 2013-04-02 Ｃｃｒ３アンタゴニストを含む医薬製剤 Active JP6320990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12163078 2012-04-04
EP12163078.4 2012-04-04
PCT/EP2013/056867 WO2013149987A1 (en) 2012-04-04 2013-04-02 Pharmaceutical formulations comprising ccr3 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018072309A Division JP6700332B2 (ja) 2012-04-04 2018-04-04 Ｃｃｒ３アンタゴニストを含む医薬製剤

Publications (3)

Publication Number Publication Date
JP2015512433A JP2015512433A (ja) 2015-04-27
JP2015512433A5 true JP2015512433A5 (enExample) 2016-06-02
JP6320990B2 JP6320990B2 (ja) 2018-05-09

Family

ID=49292482

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015503848A Active JP6320990B2 (ja) 2012-04-04 2013-04-02 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2018072309A Active JP6700332B2 (ja) 2012-04-04 2018-04-04 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2020080024A Pending JP2020143080A (ja) 2012-04-04 2020-04-30 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2022026735A Pending JP2022081524A (ja) 2012-04-04 2022-02-24 Ｃｃｒ３アンタゴニストを含む医薬製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018072309A Active JP6700332B2 (ja) 2012-04-04 2018-04-04 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2020080024A Pending JP2020143080A (ja) 2012-04-04 2020-04-30 Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2022026735A Pending JP2022081524A (ja) 2012-04-04 2022-02-24 Ｃｃｒ３アンタゴニストを含む医薬製剤

Country Status (31)

Country Link
US (3) US10213421B2 (enExample)
EP (3) EP3524230B1 (enExample)
JP (4) JP6320990B2 (enExample)
KR (2) KR102138709B1 (enExample)
CN (1) CN104203213A (enExample)
AR (1) AR090596A1 (enExample)
AU (1) AU2013245028B2 (enExample)
BR (1) BR112014024479A8 (enExample)
CA (1) CA2869058C (enExample)
CL (1) CL2014002524A1 (enExample)
CY (1) CY1121137T1 (enExample)
DK (2) DK2833864T3 (enExample)
EA (1) EA027627B1 (enExample)
ES (3) ES2715844T3 (enExample)
HR (1) HRP20190069T1 (enExample)
HU (2) HUE056943T2 (enExample)
IL (1) IL234299A (enExample)
IN (1) IN2014DN07082A (enExample)
LT (1) LT2833864T (enExample)
MX (1) MX358307B (enExample)
NZ (1) NZ628993A (enExample)
PH (1) PH12014502241A1 (enExample)
PL (2) PL3524230T3 (enExample)
PT (2) PT3524230T (enExample)
RS (1) RS58360B1 (enExample)
SI (1) SI2833864T1 (enExample)
SM (1) SMT201900121T1 (enExample)
TR (1) TR201821285T4 (enExample)
TW (1) TW201400115A (enExample)
UY (1) UY34730A (enExample)
WO (1) WO2013149987A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
ES3046717T3 (en) * 2017-04-05 2025-12-02 Alkahest Inc Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
US20190111042A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
US20230312697A1 (en) 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
KR20230056017A (ko) 2020-08-27 2023-04-26 에이지씨 가부시키가이샤 무알칼리 유리 및 유리판
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
US4992277A (en) 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
KR20010012402A (ko) * 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
AU2335699A (en) 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AU2654399A (en) 1998-02-02 1999-08-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
WO2004004716A1 (en) * 2002-07-08 2004-01-15 Chemgenex Pharmaceuticals Limited Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
SG131946A1 (en) 2003-10-24 2007-05-28 Hoffmann La Roche Ccr3 receptor antagonists
BRPI0416665A (pt) 2003-11-17 2007-01-16 Boehringer Ingelheim Int indóis substituìdos com piperidina ou heteroderivados dos mesmos
DE602005013931D1 (enExample) 2004-02-05 2009-05-28 Schering Corp
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
JP5080450B2 (ja) 2005-04-30 2012-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なピペリジン置換インドール
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
WO2007116313A2 (en) 2006-04-12 2007-10-18 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
CA2667548C (en) 2006-10-27 2015-02-03 Boehringer Ingelheim International Gmbh Substituted piperidyl-propane-thiols
ATE537166T1 (de) 2006-10-27 2011-12-15 Boehringer Ingelheim Int Piperidylpropanthiole als ccr3-modulatoren
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
NZ585438A (en) 2007-10-24 2012-09-28 Generics Uk Ltd Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
WO2010052727A1 (en) * 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
WO2010123959A2 (en) 2009-04-22 2010-10-28 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide ccr3 antagonists
PL2421829T3 (pl) * 2009-04-22 2016-03-31 Axikin Pharmaceuticals Inc 2,5-dipodstawione arylosulfonamidy jako antagoniści CCR3
EP2523654A4 (en) * 2010-01-11 2014-08-06 Mohamed Shafee Muneera IMMEDIATE RELEASE COMPOSITIONS OF MEDICAMENTS LABILES ACIDES
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Similar Documents

Publication Publication Date Title
JP2015512433A5 (enExample)
JP6700332B2 (ja) Ｃｃｒ３アンタゴニストを含む医薬製剤
JP2018021082A5 (enExample)
JP6487599B2 (ja) エスシタロプラム医薬組成物
EA039006B1 (ru) Ингибиторы тирозинкиназы
TWI750143B (zh) 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物
US11331273B2 (en) Film-coated tablet having high chemical stability of active ingredient
JP2020158435A (ja) リナグリプチン含有医薬組成物及びその製造方法、並びにリナグリプチン含有医薬組成物の品質の向上方法
KR101446129B1 (ko) 프란루카스트-함유 고형 제제의 제조방법
JP2017031117A (ja) 光安定性を向上した、イミダフェナシン製剤
WO2016079687A1 (en) Oral pharmaceutical composition of teriflunomide
JPWO2009123169A1 (ja) アミド誘導体含有医薬組成物
EP1968593B1 (en) Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
JP2016155777A (ja) モンテルカスト又はその塩を含む組成物
WO2011012987A1 (en) Pharmaceutical composition of isoniazid
JP6883401B2 (ja) アジルサルタン含有錠剤及び錠剤におけるアジルサルタンの安定化方法
JP7271869B2 (ja) レボセチリジン含有錠剤
JP2014114243A (ja) 安定な固形製剤の製造方法
JP2016222651A (ja) ミグリトール含有口腔内崩壊錠
EP3731822A1 (en) Oral pharmaceutical compositions of dabigatran
JP2019073445A (ja) アプレピタントを有効成分とする医薬組成物
JP6340270B2 (ja) 安定なモンテルカストナトリウム含有経口固形医薬組成物、その製造方法、およびモンテルカストナトリウムの類縁物質生成抑制方法
CA3038620A1 (en) Pharmaceutical compositions of 5-ht6 antagonist
JP6336651B1 (ja) 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
JP2020015690A (ja) レボセチリジン含有錠剤